C Tempfer1, L-C Horn2, S Ackermann3, M W Beckmann4, R Dittrich4, J Einenkel5, A Günthert6, H Haase7, J Kratzsch8, M C Kreissl9, S Polterauer10, A D Ebert11, K T M Schneider12, H G Strauss13, F Thiel14. 1. Universitätsfrauenklinik der Ruhr-Universität Bochum, Bochum. 2. Institut für Pathologie, Universitätsklinikum Leipzig, Leipzig. 3. Frauenklinik, Klinikum Darmstadt, Darmstadt. 4. Frauenklinik, Universitätsklinikum Erlangen, Erlangen. 5. Universitätsfrauenklinik, Universitätsklinikum Leipzig, Leipzig. 6. Frauenklinik, Luzerner Kantonsspital, Lucerne, Switzerland. 7. Frauenselbsthilfe nach Krebs, e. V. 8. Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik, Universitätsklinikum Leipzig, Leipzig. 9. Klinik für Nuklearmedizin, Klinikum Augsburg, Augsburg. 10. Universitätsfrauenklinik, Medizinische Universität Wien, Vienna, Austria. 11. Praxis für Gynäkologie und Geburtshilfe, Berlin. 12. Abteilung für Geburtshilfe und Perinatalmedizin, Klinium rechts der Isar, Technische Universität München, Munich. 13. Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle (Saale), Halle (Saale). 14. Frauenklinik, Alb Fils Kliniken, Göppingen.
Abstract
Purpose: The aim was to establish an official interdisciplinary guideline, published and coordinated by the German Society of Gynecology and Obstetrics (DGGG). The guideline was developed for use in German-speaking countries. In addition to the Germany Society of Gynecology and Obstetrics, the guideline has also been approved by the Swiss Society of Gynecology and Obstetrics (SGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). The aim was to standardize diagnostic procedures and the management of gestational and non-gestational trophoblastic disease in accordance with the principles of evidence-based medicine, drawing on the current literature and the experience of the colleagues involved in compiling the guideline. Methods: This s2k guideline represents the consensus of a representative panel of experts with a range of different professional backgrounds commissioned by the DGGG. Following a review of the international literature and international guidelines on trophoblastic tumors, a structural consensus was achieved in a formalized, multi-step procedure. This was done using uniform definitions, objective assessments, and standardized management protocols. Recommendations: The recommendations of the guideline cover the epidemiology, classification and staging of trophoblastic tumors; the measurement of human chorionic gonadotropin (hCG) levels in serum, and the diagnosis, management, and follow-up of villous trophoblastic tumors (e.g., partial mole, hydatidiform mole, invasive mole) and non-villous trophoblastic tumors (placental site nodule, exaggerated placental site, placental site tumor, epitheloid trophoblastic tumor, and choriocarcinoma).
Purpose: The aim was to establish an official interdisciplinary guideline, published and coordinated by the German Society of Gynecology and Obstetrics (DGGG). The guideline was developed for use in German-speaking countries. In addition to the Germany Society of Gynecology and Obstetrics, the guideline has also been approved by the Swiss Society of Gynecology and Obstetrics (SGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). The aim was to standardize diagnostic procedures and the management of gestational and non-gestational trophoblastic disease in accordance with the principles of evidence-based medicine, drawing on the current literature and the experience of the colleagues involved in compiling the guideline. Methods: This s2k guideline represents the consensus of a representative panel of experts with a range of different professional backgrounds commissioned by the DGGG. Following a review of the international literature and international guidelines on trophoblastic tumors, a structural consensus was achieved in a formalized, multi-step procedure. This was done using uniform definitions, objective assessments, and standardized management protocols. Recommendations: The recommendations of the guideline cover the epidemiology, classification and staging of trophoblastic tumors; the measurement of humanchorionic gonadotropin (hCG) levels in serum, and the diagnosis, management, and follow-up of villous trophoblastic tumors (e.g., partial mole, hydatidiform mole, invasive mole) and non-villous trophoblastic tumors (placental site nodule, exaggerated placental site, placental site tumor, epitheloid trophoblastic tumor, and choriocarcinoma).
Authors: Giorgia Mangili; Domenica Lorusso; Jubilee Brown; Jacobus Pfisterer; Leon Massuger; Michelle Vaughan; Hextan Y S Ngan; Francois Golfier; Paradan K Sekharan; Rafael Cortés Charry; Andres Poveda; Jae-Weon Kim; Yang Xiang; Ross Berkowtiz; Michael J Seckl Journal: Int J Gynecol Cancer Date: 2014-11 Impact factor: 3.437
Authors: Constantine Alifrangis; Roshan Agarwal; Delia Short; Rosemary A Fisher; Neil J Sebire; Richard Harvey; Philip M Savage; Michael J Seckl Journal: J Clin Oncol Date: 2012-12-10 Impact factor: 44.544
Authors: C Lybol; F C G J Sweep; R Harvey; H Mitchell; D Short; C M G Thomas; P B Ottevanger; P M Savage; L F A G Massuger; M J Seckl Journal: Gynecol Oncol Date: 2012-03-09 Impact factor: 5.482
Authors: Antonio Braga; Elza Maria Hartmann Uberti; Maria do Carmo Fajardo; Maurício Viggiano; Sue Yazaki Sun; Bruno Maurizio Grillo; Sérgio Lunardon Padilha; Jurandyr Moreira de Andrade; Christiani Bisinoto de Souza; José Mauro Madi; Izildinha Maestá; Eduardo Silveira Journal: J Reprod Med Date: 2014 May-Jun Impact factor: 0.142
Authors: Małgorzata Rzanny-Owczarzak; Joanna Sawicka-Metkowska; Katarzyna Jończyk-Potoczna; Ewelina Gowin; Patrycja Sosnowska-Sienkiewicz; Przemysław Mańkowski; Danuta Januszkiewicz-Lewandowska Journal: Int J Environ Res Public Health Date: 2021-02-17 Impact factor: 3.390